Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.33 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CDC7 | O00311 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12833114 | 1.00 | ALDH1A1 (0.39) | ALDH1A1ALOX5RAB9AMAPK1KDM4E | |
| SCHEMBL19398564 | 0.86 | MAPK1 (0.38) | ALDH1A1ALOX5RAB9AMAPK1L3MBTL1 | |
| SCHEMBL1505266 | 0.83 | MAPT (0.38) | ALDH1A1RAB9AKDM4EADORA2AADORA1 | |
| SCHEMBL12506974 | 0.83 | ADORA2A (0.39) | ALDH1A1RAB9AKDM4EL3MBTL1ADORA2A | |
| SCHEMBL1929144 | 0.83 | ADORA2A (0.39) | ALDH1A1RAB9AKDM4EL3MBTL1ADORA2A | |
| SCHEMBL1505257 | 0.83 | ADORA2A (0.39) | ALDH1A1RAB9AKDM4EL3MBTL1ADORA2A | |
| SCHEMBL1294099 | 0.82 | CYP1A2 (0.37) | ALDH1A1RAB9AKDM4EPDGFRBGSK3B | |
| SCHEMBL1759052 | 0.82 | CYP1A2 (0.37) | ALDH1A1RAB9AKDM4EPDGFRBGSK3B | |
| Hydrochloric Acid SCHEMBL19329630 | 0.81 | ADORA1 (0.38) | ALDH1A1RAB9AKDM4EL3MBTL1ADORA2A | |
| SCHEMBL1927811 | 0.78 | RPS6KB1 (0.35) | ALDH1A1ALOX5RAB9AMAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3112352-B1 | OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-21 | — | — | EP | disclosed |
| US-20180325870-A1 | NOVEL COMPOUNDS AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2018-11-15 | — | — | US | disclosed |
| US-9700542-B2 | Compounds as opioid receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-11 | — | — | US | disclosed |
| EP-3112352-A1 | OPIOID RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2017-01-04 | — | — | EP | disclosed |
| EP-2653465-B1 | Opioid receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-13 | — | — | EP | disclosed |
| US-20160030393-A1 | NOVEL COMPOUNDS AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-04 | — | — | US | disclosed |
| US-9205076-B2 | Compounds as opioid receptor modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2015-12-08 | — | — | US | disclosed |
| EP-2573068-B9 | Process for preparing intermediates of compounds useful as opioid receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-26 | — | — | EP | disclosed |
| EP-2573068-B1 | Process for preparing intermediates of compounds useful as opioid receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-31 | — | — | EP | disclosed |
| US-20140256779-A1 | NOVEL COMPOUNDS AS OPIOID RECEPTOR MODULATORS | JANNSEN PHARMACEUTICA, N.V. (BE) | 2014-09-11 | — | — | US | disclosed |
| EP-1725537-B1 | NOVEL COMPOUNDS AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-07-13 | — | — | EP | disclosed |
| EP-2298744-A2 | Opioid receptor modulators | Janssen Pharmaceutica NV (BE) | 2011-03-23 | — | — | EP | disclosed |
| US-20100324051-A1 | NOVEL COMPOUNDS AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-12-23 | — | — | US | disclosed |
| US-7786158-B2 | pain relievers; gastrointestinal disorders; inflammatory bowel disease, diarrhea, motility disorders; aminoacetamide derivatives substituted with an imidazole; 5-(([2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino)-methyl)-2-methoxy-benzoic acid | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-31 | — | — | US | disclosed |
| US-7741356-B2 | use as pain relievers, gastrointestinal disorders such as inflammatory bowel disease; compounds are aminoacetamide derivatives substituted with an imidazole; 5-(([2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino)-methyl)-2-methoxy-benzoic acid for example | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-06-22 | — | — | US | disclosed |
| US-20080096888-A1 | pain relievers; gastrointestinal disorders; inflammatory bowel disease, diarrhea, motility disorders; aminoacetamide derivatives substituted with an imidazole; 5-(([2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino)-methyl)-2-methoxy-benzoic acid | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-04-24 | — | — | US | disclosed |
| CN-1950342-A | Novel compounds as opioid receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2007-04-18 | — | — | CN | disclosed |
| EP-1725537-A1 | NOVEL COMPOUNDS AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005090315-A1 | NOVEL COMPOUNDS AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N. V. (BE) | 2005-09-29 | — | — | WO | disclosed |
| US-20050203143-A1 | use as pain relievers, gastrointestinal disorders such as inflammatory bowel disease; compounds are aminoacetamide derivatives substituted with an imidazole; 5-(([2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino)-methyl)-2-methoxy-benzoic acid for example | JANSSEN PHARMACEUTICA, N. V. (BE) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203143-A1 | use as pain relievers, gastrointestinal disorders such as inflammatory bowel disease; compounds are aminoacetamide derivatives substituted with an imidazole; 5-(([2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino)-methyl)-2-methoxy-benzoic acid for example | OPRK1, OPRM1, OPRL1 | ALDH1A1 982/4885ALOX5 307/4885RAB9A 2830/4885 |
| US-20100324051-A1 | NOVEL COMPOUNDS AS OPIOID RECEPTOR MODULATORS | OPRM1, OPRK1, OPRL1 | ALDH1A1 770/4885ALOX5 812/4885RAB9A 1077/4885 |
| US-20160030393-A1 | NOVEL COMPOUNDS AS OPIOID RECEPTOR MODULATORS | OPRM1, OPRK1, OPRL1 | ALDH1A1 770/4885ALOX5 812/4885RAB9A 1077/4885 |
| US-20080096888-A1 | pain relievers; gastrointestinal disorders; inflammatory bowel disease, diarrhea, motility disorders; aminoacetamide derivatives substituted with an imidazole; 5-(([2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino)-methyl)-2-methoxy-benzoic acid | OPRK1, OPRM1, OPRL1 | ALDH1A1 1178/4885ALOX5 522/4885RAB9A 2240/4885 |
| US-20140256779-A1 | NOVEL COMPOUNDS AS OPIOID RECEPTOR MODULATORS | OPRM1, OPRK1, OPRL1 | ALDH1A1 770/4885ALOX5 812/4885RAB9A 1077/4885 |
| US-20180325870-A1 | NOVEL COMPOUNDS AS OPIOID RECEPTOR MODULATORS | OPRM1, OPRK1, OPRL1 | ALDH1A1 770/4885ALOX5 812/4885RAB9A 1077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.